Trial Profile
Drug Use Investigation of Sorafenib/ NEXAVAR(R) for Unresectable Differentiated Thyroid Carcinoma (DTC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Adverse reactions
- Acronyms JPMS-DTC
- Sponsors Bayer
- 12 Jan 2021 Planned End Date changed from 30 Jun 2021 to 30 Jun 2024.
- 12 May 2020 Status changed from recruiting to active, no longer recruiting.
- 21 Apr 2017 Planned End Date changed from 30 Jun 2018 to 30 Jun 2021.